The value in the PRV is actually NOT selling it. The faster paxalisib is brought to market then the faster it can be used in multiple indications. Unless, the whole drug and PRV is on sold.
Ann: Kazia Annual Report to shareholders, page-13
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)